Proceeds to support the advancement of Neumora’s mission of building a leading global precision neuroscience company to revolutionize the treatment of brain diseases Approximately $650 million in capital raised to date provides strong financial position through multiple near-term, value-creating milestones WATERTOWN, Ma.--(BUSINESS WIRE)--Neumora Therapeutics, Inc. (Neumora), a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the